Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
26 hedge funds and large institutions have $3.23M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
4% less funds holding
Funds holding: 27 → 26 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
48% less capital invested
Capital invested by funds: $6.18M → $3.23M (-$2.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$315K |
| 2 |
AI
Arena Investors
Purchase,
New York
|
+$73.9K |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
+$35.4K |
| 4 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$12.5K |
| 5 |
CAC
Cowen and Company
New York
|
+$5.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AMH
Apollo Management Holdings
New York
|
-$348K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$123K |
| 3 |
GL
Governors Lane
New York
|
-$67K |
| 4 |
CCFM
Cohen & Co Financial Management
New York
|
-$25K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4K |
CLDI.WS Hedge Fund Activity: Q2 2022 in Review
26 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q2 2022, worth a combined $3.23M — down 48% from $6.18M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CLDI.WS and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 6 added.
The largest buyer was Polar Asset Management Partners, adding an estimated $315K. The largest seller was Apollo Management Holdings, exiting entirely with an estimated $348K sold.
- 26 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q2 2022, down from 27 in Q1 2022.
- Funds reported $3.23M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q2 2022, down 48% quarter-over-quarter.
- 3 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q2 2022 and 4 closed out, a net change of -1 holder.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q2 2022 was Polar Asset Management Partners, an estimated $315K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q2 2022 was Apollo Management Holdings, an estimated $348K sold.
Based on aggregated 13F filings for Q2 2022.